Gapping down
In reaction to earnings/guidance:
- BYND -22.3% (saw deterioration of its foodservice business as COVID-19 stay-at-home measures set in), ARNA -17.7%, NBIX -11.7%, RAMP -9.9%, TLRY -7.3%, CYBR -7.1%, REAL -7%, NVAX -4.5% (also names new CFO), IFF -3.9%, SPG -3.6%, ROK -3.4%, AER -3.1%, ZGNX -2.6%, RPAY -2.2%, AMBC -1.9%, ELY -1.7%, VITL -1.3%, IHRT -1%
Other news:
- ARNA -17.7% (announces primary endpoint not met in top line results from Phase 2b ADVISE trial; also reports earnings)
- OGI -14.4% (announced underwritten public offering of units whereby a syndicate of underwriters agreed to purchase 32,500,000 Units from the Company at a price of C$1.85 per Unit)
- TXMD -9.9% (stock offering)
- RVNC -5.8% (says Phase 2 trial for plantar fasciitis; primary efficacy endpoint not met)
- FSR -4.8% (stock offerings),
- NVAX -4.8% (files to delay form 10-Q)
- FBIO -3.4% (stock offering)
- SSTI -3.4% (to acquire Leeds)
- NLS -3.2% (files for $100 mln mixed securities shelf offering)
- ERIC -3.1% (provides short and long-term objectives at its Capital Markets Day)
- ACTG -2.8% (stock offerings)
- AVEO -2% (files for $300 mln mixed securities shelf offering)
- AMZN -1.7% (EU commission sends statement of objections to Amazon for the use of non-public independent seller data and opens second investigation into its e-commerce business practices)
Analyst comments:
- CHMI -4.4% (downgraded to Neutral from Overweight at Piper Sandler)
- FSLR -3% (downgraded to Underperform from Outperform at Raymond James)
- SLRC -0.8% (downgraded to Equal Weight from Overweight at Wells Fargo)